Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

Open access
Rivera, Luis, Biswal, Shibadas, Sáez-Llorens, Xavier, Reynales, Humberto, López-Medina, Eduardo, Borja-Tabora, Charissa, Bravo, Lulu, Sirivichayakul, Chukiat, Kosalaraksa, Pope, Martinez Vargas, Luis, Yu, Delia, Watanaveeradej, Veerachai, Espinoza, Felix, Dietze, Reynaldo, Fernando, LakKumar, Wickramasinghe, Pujitha, Duarte MoreiraJr, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, Venâncioda Cunha, Rivaldo, Rauscher, Martina, Zent, Olaf, Liu, Mengya, Hoffman, Elaine, LeFevre, Inge, Tricou, Vianney, Wallace, Derek, Alera, MariaTheresa, Borkowski, Astrid·2022·Clinical Infectious Diseases

Abstract

Background: Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in both seronegative and seropositive participants and that its performance varies by serotype, with some decline in efficacy from first to second year postvaccination. This exploratory analysis provides an update with cumulative and third-year data. Methods: Healthy 4–16 year olds (n = 20099) were randomized 2:1 to receive TAK-003 or placebo (0, 3 month schedule). The protocol included baseline serostatus testing of all participants and detection of all symptomatic dengue throughout the trial with a serotype specific reverse transcriptase-polymerase chain reaction. Results: Cumulative efficacy after 3 years was 62.0% (95% confidence interval, 56.6–66.7) against virologically confirmed dengue (VCD) and 83.6% (76.8–88.4) against hospitalized VCD. Efficacy was 54.3% (41.9–64.1) against VCD and 77.1% (58.6–87.3) against hospitalized VCD in baseline seronegatives, and 65.0% (58.9–70.1) against VCD and 86.0% (78.4–91.0) against hospitalized VCD in baseline seropositives. Efficacy against VCD during the third year declined to 44.7% (32.5–54.7), whereas efficacy against hospitalized VCD was sustained at 70.8% (49.6–83.0). Rates of serious adverse events were 2.9% in TAK-003 group and 3.5% in placebo group during the ongoing long-term follow-up (ie, second half of the 3 years following vaccination), but none were related. No important safety risks were identified. Conclusions: TAK-003 was efficacious against symptomatic dengue over 3 years. Efficacy declined over time but remained robust against hospitalized dengue. A booster dose evaluation is planned.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciab864

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 243

Metadata

Authors
Rivera, L., Biswal, S., Sáez-Llorens, X., Reynales, H., López-Medina, E., Borja-Tabora, C., Bravo, L., Sirivichayakul, C., Kosalaraksa, P., Martinez Vargas, L., Yu, D., Watanaveeradej, V., Espinoza, F., Dietze, R., Fernando, L., Wickramasinghe, P., Duarte MoreiraJr, E., Fernando, A. D., Gunasekera, D., Luz, K., Venâncioda Cunha, R., Rauscher, M., Zent, O., Liu, M., Hoffman, E., LeFevre, I., Tricou, V., Wallace, D., Alera, M., & Borkowski, A.
Venue
Clinical Infectious Diseases
Published
2021-10-04
Volume
75
Issue
1
Pages
107-117
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3203455658
Cited by
243
References
2
FWCI
27.94
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003). https://app.cochat.ai/papers/10.1093/cid/ciab864
The paper
Rivera, L., Biswal, S., Sáez-Llorens, X., Reynales, H., López-Medina, E., Borja-Tabora, C., Bravo, L., Sirivichayakul, C., Kosalaraksa, P., Martinez Vargas, L., Yu, D., Watanaveeradej, V., Espinoza, F., Dietze, R., Fernando, L., Wickramasinghe, P., Duarte MoreiraJr, E., Fernando, A. D., Gunasekera, D., . . . Borkowski, A. (2022). Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab864

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.